Figure 3. Effects of treatment with either fisetin or LY294002 on EGF-induced AKT activation in ARPE-19 cells. A: ARPE-19 cells were treated with epidermal growth factor (EGF; 20 ng/ml) or were cotreated with EGF (20 ng/ml) plus fisetin
(5 μM) plus LY294002 (30 μM) for 24 h; western blots show p-AKT, t-AKT, and matrix metallopeptidase-9 (MMP-9) expression.
The reverse transcription–PCR (RT–PCR) assay shows MMP-9 mRNA expression. B: The migratory abilities of cells were determined using an in vitro migration assay. Quantification of migrated cells is
shown as a histogram. Data are presented as the mean ± standard error of the mean (SEM) of at least three independent experiments.
β-actin was used as an internal control. **p<0.01 compared with control cells; #p<0.01 compared with fisetin.